Pharmacogenomics Market to 2027 - Global Analysis and Forecasts byTechnology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others); Application (Neurology, Oncology, Pain Management, Other); End-User (Biopharmaceutical Companies, Clinical Research Organizations/Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO)
Report Code: TIPRE00007564 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Pharmacogenomics is an essential characteristic feature of precision medicine, which allows for an individual's genetic makeup affects and their response to a therapeutic drug. Although tailor-made medication dosing, there still are a large number of cases involving adverse drug reactions, leading to frequent dose titration and iteration concerning treatment. With all these things, these factors impose a significant burden on the patient, provider, and the overall healthcare system.
MARKET DYNAMICS
The pharmacogenomics market is expected to grow significantly in the coming years, owing to the key factors such as rising research and development activities by the major pharmaceutical companies, and increasing focus on precision medicine. The developing regions are likely to serve more growth opportunities in coming years due to increasing in strategic initiative taken by key players.
MARKET SCOPE
The “Global Pharmacogenomics Market Analysis to 2027” is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of pharmacogenomics market with detailed market segmentation by type, application, end user and geography. The global pharmacogenomics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading pharmacogenomics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global pharmacogenomics market is segmented on the basis of technology, application and end user. On the basis of technology, the market is segmented into DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others. Based on the application the market is divided into Drug Discovery, Neurology, Oncology, Pain Management, Other. On the basis of end user, the market is segmented into biopharmaceutical companies, clinical research organizations/contract research organizations, and contract development and manufacturing organization (CDMO).
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Pharmacogenomics Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Pharmacogenomics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Pharmacogenomics Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pharmacogenomics Market in these regions.
The reports cover key developments in the pharmacogenomics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from pharmacogenomics market are anticipated to lucrative growth opportunities in the future with the rising demand for pharmacogenomics market in the global market. Below mentioned is the list of few companies engaged in the bioanalytical testing services market.
The report also includes the profiles of key pharmacogenomics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Abbott.
- bioMérieux SA
- AstraZeneca
- Bayer AG
- BD
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN.
- Thermo Fisher Scientific Inc.
The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pharmacogenomics Market - By Technology
1.3.2 Pharmacogenomics Market - By Application
1.3.3 Pharmacogenomics Market - By End-User
1.3.4 Pharmacogenomics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PHARMACOGENOMICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PHARMACOGENOMICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PHARMACOGENOMICS MARKET - GLOBAL MARKET ANALYSIS
6.1. PHARMACOGENOMICS - GLOBAL MARKET OVERVIEW
6.2. PHARMACOGENOMICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PHARMACOGENOMICS MARKET - REVENUE AND FORECASTS TO 2027 – TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. DNA SEQUENCING
7.3.1. Overview
7.3.2. DNA Sequencing Market Forecast and Analysis
7.4. MICROARRAY
7.4.1. Overview
7.4.2. Microarray Market Forecast and Analysis
7.5. POLYMERASE CHAIN REACTION
7.5.1. Overview
7.5.2. Polymerase Chain Reaction Market Forecast and Analysis
7.6. ELECTROPHORESIS
7.6.1. Overview
7.6.2. Electrophoresis Market Forecast and Analysis
7.7. MASS SPECTROMETRY
7.7.1. Overview
7.7.2. Mass Spectrometry Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. PHARMACOGENOMICS MARKET - REVENUE AND FORECASTS TO 2027 – APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. NEUROLOGY
8.3.1. Overview
8.3.2. Neurology Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. PAIN MANAGEMENT
8.5.1. Overview
8.5.2. Pain Management Market Forecast and Analysis
8.6. OTHER
8.6.1. Overview
8.6.2. Other Market Forecast and Analysis
9. PHARMACOGENOMICS MARKET - REVENUE AND FORECASTS TO 2027 – END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. BIOPHARMACEUTICAL COMPANIES
9.3.1. Overview
9.3.2. Biopharmaceutical Companies Market Forecast and Analysis
9.4. CLINICAL RESEARCH ORGANIZATIONS/CONTRACT RESEARCH ORGANIZATIONS
9.4.1. Overview
9.4.2. Clinical Research Organizations/Contract Research Organizations Market Forecast and Analysis
9.5. CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)
9.5.1. Overview
9.5.2. Contract Development and Manufacturing Organization (CDMO) Market Forecast and Analysis
10. PHARMACOGENOMICS MARKET REVENUE AND FORECASTS TO 2027 – GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Pharmacogenomics Market Overview
10.1.2 North America Pharmacogenomics Market Forecasts and Analysis
10.1.3 North America Pharmacogenomics Market Forecasts and Analysis - By Technology
10.1.4 North America Pharmacogenomics Market Forecasts and Analysis - By Application
10.1.5 North America Pharmacogenomics Market Forecasts and Analysis - By End-User
10.1.6 North America Pharmacogenomics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Pharmacogenomics Market
10.1.6.1.1 United States Pharmacogenomics Market by Technology
10.1.6.1.2 United States Pharmacogenomics Market by Application
10.1.6.1.3 United States Pharmacogenomics Market by End-User
10.1.6.2 Canada Pharmacogenomics Market
10.1.6.2.1 Canada Pharmacogenomics Market by Technology
10.1.6.2.2 Canada Pharmacogenomics Market by Application
10.1.6.2.3 Canada Pharmacogenomics Market by End-User
10.1.6.3 Mexico Pharmacogenomics Market
10.1.6.3.1 Mexico Pharmacogenomics Market by Technology
10.1.6.3.2 Mexico Pharmacogenomics Market by Application
10.1.6.3.3 Mexico Pharmacogenomics Market by End-User
10.2. EUROPE
10.2.1 Europe Pharmacogenomics Market Overview
10.2.2 Europe Pharmacogenomics Market Forecasts and Analysis
10.2.3 Europe Pharmacogenomics Market Forecasts and Analysis - By Technology
10.2.4 Europe Pharmacogenomics Market Forecasts and Analysis - By Application
10.2.5 Europe Pharmacogenomics Market Forecasts and Analysis - By End-User
10.2.6 Europe Pharmacogenomics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Pharmacogenomics Market
10.2.6.1.1 Germany Pharmacogenomics Market by Technology
10.2.6.1.2 Germany Pharmacogenomics Market by Application
10.2.6.1.3 Germany Pharmacogenomics Market by End-User
10.2.6.2 France Pharmacogenomics Market
10.2.6.2.1 France Pharmacogenomics Market by Technology
10.2.6.2.2 France Pharmacogenomics Market by Application
10.2.6.2.3 France Pharmacogenomics Market by End-User
10.2.6.3 Italy Pharmacogenomics Market
10.2.6.3.1 Italy Pharmacogenomics Market by Technology
10.2.6.3.2 Italy Pharmacogenomics Market by Application
10.2.6.3.3 Italy Pharmacogenomics Market by End-User
10.2.6.4 Spain Pharmacogenomics Market
10.2.6.4.1 Spain Pharmacogenomics Market by Technology
10.2.6.4.2 Spain Pharmacogenomics Market by Application
10.2.6.4.3 Spain Pharmacogenomics Market by End-User
10.2.6.5 United Kingdom Pharmacogenomics Market
10.2.6.5.1 United Kingdom Pharmacogenomics Market by Technology
10.2.6.5.2 United Kingdom Pharmacogenomics Market by Application
10.2.6.5.3 United Kingdom Pharmacogenomics Market by End-User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Pharmacogenomics Market Overview
10.3.2 Asia-Pacific Pharmacogenomics Market Forecasts and Analysis
10.3.3 Asia-Pacific Pharmacogenomics Market Forecasts and Analysis - By Technology
10.3.4 Asia-Pacific Pharmacogenomics Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Pharmacogenomics Market Forecasts and Analysis - By End-User
10.3.6 Asia-Pacific Pharmacogenomics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Pharmacogenomics Market
10.3.6.1.1 Australia Pharmacogenomics Market by Technology
10.3.6.1.2 Australia Pharmacogenomics Market by Application
10.3.6.1.3 Australia Pharmacogenomics Market by End-User
10.3.6.2 China Pharmacogenomics Market
10.3.6.2.1 China Pharmacogenomics Market by Technology
10.3.6.2.2 China Pharmacogenomics Market by Application
10.3.6.2.3 China Pharmacogenomics Market by End-User
10.3.6.3 India Pharmacogenomics Market
10.3.6.3.1 India Pharmacogenomics Market by Technology
10.3.6.3.2 India Pharmacogenomics Market by Application
10.3.6.3.3 India Pharmacogenomics Market by End-User
10.3.6.4 Japan Pharmacogenomics Market
10.3.6.4.1 Japan Pharmacogenomics Market by Technology
10.3.6.4.2 Japan Pharmacogenomics Market by Application
10.3.6.4.3 Japan Pharmacogenomics Market by End-User
10.3.6.5 South Korea Pharmacogenomics Market
10.3.6.5.1 South Korea Pharmacogenomics Market by Technology
10.3.6.5.2 South Korea Pharmacogenomics Market by Application
10.3.6.5.3 South Korea Pharmacogenomics Market by End-User
10.3.6.6 Indonesia Pharmacogenomics Market
10.3.6.6.1 Indonesia Pharmacogenomics Market by Technology
10.3.6.6.2 Indonesia Pharmacogenomics Market by Application
10.3.6.6.3 Indonesia Pharmacogenomics Market by End-User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Pharmacogenomics Market Overview
10.4.2 Middle East and Africa Pharmacogenomics Market Forecasts and Analysis
10.4.3 Middle East and Africa Pharmacogenomics Market Forecasts and Analysis - By Technology
10.4.4 Middle East and Africa Pharmacogenomics Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Pharmacogenomics Market Forecasts and Analysis - By End-User
10.4.6 Middle East and Africa Pharmacogenomics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Pharmacogenomics Market
10.4.6.1.1 South Africa Pharmacogenomics Market by Technology
10.4.6.1.2 South Africa Pharmacogenomics Market by Application
10.4.6.1.3 South Africa Pharmacogenomics Market by End-User
10.4.6.2 Saudi Arabia Pharmacogenomics Market
10.4.6.2.1 Saudi Arabia Pharmacogenomics Market by Technology
10.4.6.2.2 Saudi Arabia Pharmacogenomics Market by Application
10.4.6.2.3 Saudi Arabia Pharmacogenomics Market by End-User
10.4.6.3 U.A.E Pharmacogenomics Market
10.4.6.3.1 U.A.E Pharmacogenomics Market by Technology
10.4.6.3.2 U.A.E Pharmacogenomics Market by Application
10.4.6.3.3 U.A.E Pharmacogenomics Market by End-User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Pharmacogenomics Market Overview
10.5.2 South and Central America Pharmacogenomics Market Forecasts and Analysis
10.5.3 South and Central America Pharmacogenomics Market Forecasts and Analysis - By Technology
10.5.4 South and Central America Pharmacogenomics Market Forecasts and Analysis - By Application
10.5.5 South and Central America Pharmacogenomics Market Forecasts and Analysis - By End-User
10.5.6 South and Central America Pharmacogenomics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Pharmacogenomics Market
10.5.6.1.1 Brazil Pharmacogenomics Market by Technology
10.5.6.1.2 Brazil Pharmacogenomics Market by Application
10.5.6.1.3 Brazil Pharmacogenomics Market by End-User
10.5.6.2 Argentina Pharmacogenomics Market
10.5.6.2.1 Argentina Pharmacogenomics Market by Technology
10.5.6.2.2 Argentina Pharmacogenomics Market by Application
10.5.6.2.3 Argentina Pharmacogenomics Market by End-User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PHARMACOGENOMICS MARKET, KEY COMPANY PROFILES
12.1. ABBOTT.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOMéRIEUX SA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BAYER AG
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BD
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BIO-RAD LABORATORIES, INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE LTD
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ILLUMINA, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. QIAGEN.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. THERMO FISHER SCIENTIFIC INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Abbott.
2. bioMérieux SA
3. AstraZeneca
4. Bayer AG
5. BD
6. Bio-Rad Laboratories, Inc.
7. F. Hoffmann-La Roche Ltd
8. Illumina, Inc.
9. QIAGEN.
10. Thermo Fisher Scientific Inc.